Teva Pharma (TEVA) Receives U.S. Approval of Generic Tribenzor Tabs

November 7, 2016 9:02 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced approval of generic Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the U.S. and is in the final stages of launch preparation. Teva also recently received approval and launched generic Azor®2 (amlodipine and olmesartan medoxomil) tablets in the U.S. These products enhance Teva’s antihypertensive portfolio.

Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin II

receptor blocker, a dihydropyridine calcium channel blocker and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure.

Amlodipine and olmesartan medoxomil tablets are a dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Many patients will require more than one drug to achieve their blood pressure goals.

Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. These products enhance Teva’s already comprehensive product portfolio.

Teva has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Tribenzor® had annual sales of approximately $240 million in the U.S. and Azor® had annual sales of approximately $354.1 million in the U.S., according to IMS data as of August 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

Definitive Agreement

Add Your Comment